SCHEMBL3911665

SCHEMBL3911665

ClC(Cl)c1ccccc1Sc1ccccc1C(Cl)Cl

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10621286 0.80
SCHEMBL587834 0.80 GABRA1 (0.34) TSHR
SCHEMBL3785333 0.76 TSHR (0.50) TSHR
SCHEMBL10338763 0.75 CYP1A2 (0.32)
SCHEMBL4808650 0.74 GABRA1 (0.48) TSHR
SCHEMBL30389926 0.74 GABRA1 (0.48) TSHR
SCHEMBL588784 0.70 GABRA1 (0.39) TSHR
SCHEMBL5422503 0.70 GABRA1 (0.34) TSHR
SCHEMBL4143745 0.70 P2RX7 (0.37) TSHR
SCHEMBL7306128 0.69 TSHR (0.36) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1604964-B1 ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL SEKISUI CHEMICAL CO LTD (JP) 2009-06-10 EP disclosed
EP-1431302-B1 PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS SEKISUI CHEMICAL CO LTD (JP) 2009-03-18 EP disclosed
US-7361776-B2 Zero-valent transition metal complex and method for producing an organometallic compound using the same as a starting material SEKISUI CHEMICAL CO., LTD. (JP) 2008-04-22 US disclosed
US-7098355-B2 Process for synthesis of organometallic compounds SEKISUI CHEMICAL CO., LTD. (JP) 2006-08-29 US disclosed
US-20060149088-A1 Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material SEKISUI CHEMICAL CO., LTD. (JP) 2006-07-06 US disclosed
US-20060030723-A1 Process for synthesis of organometallic compounds SEKISUI CHEMICAL CO., LTD. (JP) 2006-02-09 US disclosed
EP-1604964-A1 ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL SEKISUI CHEMICAL CO., LTD. (JP) 2005-12-14 EP disclosed
EP-1431302-A1 PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS SEKISUI CHEMICAL CO., LTD. (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030723-A1 Process for synthesis of organometallic compounds CYP4F12, CYP4F2, CYP4F11 TSHR 3234/4885
US-20060149088-A1 Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material OSTC, PORCN, SQLE TSHR 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.